Prognostic Value of Systemic Immune Inflammation Index in Malignant Ischemic Stroke: A Study on Patient Selection and Timing of Surgical Decompression
Journal Title: Journal of European Internal Medicine Professionals (JEIMP) - Year 2023, Vol 1, Issue 4
Abstract
Background: Ischemic stroke is a substantial health concern with long-term neurological consequences and economic implications. Inflammation worsens secondary brain injury, prompting the search for prognostic biomarkers. The optimal approach for treating malignant ischemic stroke, patient selection, and intervention timing remain intricate due to patient diversity. Methods: We investigate the systemic immune inflammation index (SII) predictive value for surgical decompression timing and patient selection in malignant ischemic stroke. We include patients who underwent surgical decompression for ischemic stroke-induced malignant brain edema in the past five years. Retrospective data were collected, including demographics, history, laboratory results, imaging, and surgical details. SII was calculated using platelet, neutrophil, and lymphocyte counts. Descriptive statistics and multivariate regression models were used. Results: In this study involving 80 patients, we evaluated the impact of decompressive craniectomy on ischemic stroke outcomes. Patients were divided into the Decompression Group (n=39) and Non-Decompression Group (n=41). Gender distribution, hypertension, diabetes mellitus, atrial fibrillation, and hemorrhage occurrence showed no significant differences between the groups. However, the Decompression Group had higher NIHSS scores at presentation (18.1±4.6 vs. 14.8±4.7, P=0.02) and discharge (17±5 vs. 11.2±4, P=0.001). SII at presentation and control were significantly higher in the Decompression Group (P=0.04 and P=0.05, respectively). Hospitalization duration on the 10th day was longer in the Decompression Group (39.5±28.8 vs. 11.8±5.6, P=0.001). Conclusions: Our study examines SII's potential as a prognostic marker for surgical decompression timing and patient selection in malignant ischemic stroke. Despite limitations, we highlight the complex relationship between systemic inflammation, stroke severity, and post-surgical outcomes. Further research with larger cohorts must validate SII's utility and refine its application in ischemic stroke management. Continued investigation is crucial to establish SII's role as a predictive tool in guiding clinical decisions.
Authors and Affiliations
Tolga Gediz, Elif Gencer
Keywords
Related Articles
- EP ID EP733908
- DOI https://doi.org/10.5281/zenodo.10019794
- Views 73
- Downloads 1
Rheumatic Diseases and Heart
Rheumatic diseases are generally examined in three different classes; joint diseases, autoimmune connective tissue diseases, and vasculitides. They progress with significant cardiac involvement in all three groups. Card...
A Rare Complication in a Peritoneal Dialysis Patient: Hydrothorax in Late Period
Peritoneal dialysis (PD) associated hydrothorax is a rare complication caused by leakage of dialysis fluid from the peritoneal cavity into the pleural space. The typical clinical presentation is a right-sided pleural eff...
Are Allergic Diseases a Risk Factor for Systemic Side Effects After COVID-19 Vaccines?
Background: In clinical trials of currently-approved COVID-19 vaccines, patients with a known allergy or a history of anaphylaxis were excluded from the studies. This situation creates doubts about the risk and type of s...
The Other Side of The Coin in Assisted Peritoneal Dialysis
Background: Assisted peritoneal dialysis (aPD) has long been used worldwide to treat elderly and frail patients with end-stage renal disease. In developed countries, aPD is provided by health professionals, while in dev...
Canakinumab For The Treatment of Amyloidosis Secondary to Lung Cancer
hakanozer724@gmail.com, yozturk29@gmail.com, dr.fyonet@gmail.com, i_baloglu@hotmail.com, ucmdkt@gmail.com